Tirzepatide
Tirzepatide is a dual-action medication that activates both GIP and GLP-1 receptors, two key fullness and blood sugar hormones. It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management, outperforming semaglutide in head-to-head trials.
Verified sources for Tirzepatide
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Tirzepatide
Dual agonist that activates both GIP and GLP-1 receptors, producing synergistic effects on appetite suppression, insulin secretion, and energy metabolism.
Activates GLP-1 receptors in the brain, suppressing appetite and increasing satiety signals.
GIP receptor activation may complement satiety effects (proposed), contributing to enhanced weight loss beyond GLP-1-only agonists.
Activates GIP receptors with equal affinity to native GIP, enhancing insulin secretion and improving adipose tissue function.
Activates GLP-1 receptors for glucose-dependent insulin secretion, lowering blood sugar without hypoglycemia risk.
Improves pancreatic beta cell function and insulin sensitivity, which is beneficial for glucose-dependent metabolism.
Delays gastric emptying, prolonging digestion and promoting fullness.
Improves lipid profiles and reduces blood pressure, showing cardioprotective effects in clinical trials
Read Full Tirzepatide Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Metabolic & Weight Loss
Are Oral Peptides Here? Inside the Breakthrough and What's Next
Oral semaglutide just proved cardiovascular benefit, Eli Lilly cleared Phase 3, and a microneedle pill raised a billion dollars. Where the oral peptide era actually stands, and what it means for research peptides.
UPDATE: Retatrutide Clears First Phase 3 Diabetes Trial — 16.8% Weight Loss, 2.0% A1C Drop
Eli Lilly’s triple-agonist retatrutide delivered superior A1C and weight reductions in its first Phase 3 diabetes trial. Full TRANSCEND-T2D-1 breakdown.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
Retatrutide Phase 3 Results: 28.7% Weight Loss and Beyond
Eli Lilly's triple-agonist retatrutide delivered record-breaking weight loss in the TRIUMPH-4 trial. Here's what the Phase 3 data means for the future of obesity treatment.